ClinicalTrialsFinder
RecruitingACTRN12619000660189

Topical Dorzolamide for Idiopathic Macular Hole

A randomised clinical trial, to evaluate the efficacy of topical dorzolamide for the treatment of idiopathic macular hole

Sponsor

South Australian Institute of Ophthalmology

Enrollment

26 participants

Start Date

Feb 28, 2020

Study Type

Interventional

Conditions

Idiopathic macular hole

Summary

This randomised controlled trial will assess the efficacy of topical dorzolamide achieving macular hole closure prior to vitreoretinal surgery.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria3

  • Ability to provide informed consent and complete study assessments
  • Age 18 years or older
  • Idiopathic macular hole in study eye

Exclusion Criteria2

  • Renal impairment with creatinine clearance <30ml/min.
  • Other retinal pathology

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

In this double blinded study, those randomised to treatment will receive 2% dorzolamide drops to the eye three times per day for 8 weeks. Drops will be self administered by the patient following detai

In this double blinded study, those randomised to treatment will receive 2% dorzolamide drops to the eye three times per day for 8 weeks. Drops will be self administered by the patient following detailed instruction and will not be supervised.

Locations(1)

The Royal Adelaide Hospital - Adelaide

SA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12619000660189